Home Cart Sign in  
Chemical Structure| 1001414-56-7 Chemical Structure| 1001414-56-7
Chemical Structure| 1001414-56-7

(5-Bromothiophen-2-yl)methanamine hydrochloride

CAS No.: 1001414-56-7

4.5 *For Research Use Only !

Cat. No.: A270417 Purity: 97%

Change View

Size Price

US Stock

Global Stock

In Stock
1g ł§ò¶ÊÊ Inquiry Inquiry
5g łÇ§î¶ÊÊ Inquiry Inquiry
10g łËÍͶÊÊ Inquiry Inquiry
25g łÍòͶÊÊ Inquiry Inquiry

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1g

    ł§ò¶ÊÊ

  • 5g

    łÇ§î¶ÊÊ

  • 10g

    łËÍͶÊÊ

  • 25g

    łÍòͶÊÊ

In Stock

- +

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of [ 1001414-56-7 ]

CAS No. :1001414-56-7
Formula : C5H7BrClNS
M.W : 228.54
SMILES Code : NCC1=CC=C(Br)S1.[H]Cl
MDL No. :MFCD08752581
InChI Key :DWYVWUCEDHIAMH-UHFFFAOYSA-N
Pubchem ID :42888202

Safety of [ 1001414-56-7 ]

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Computational Chemistry of [ 1001414-56-7 ] Show Less

Physicochemical Properties

Num. heavy atoms 9
Num. arom. heavy atoms 5
Fraction Csp3 0.2
Num. rotatable bonds 1
Num. H-bond acceptors 1.0
Num. H-bond donors 1.0
Molar Refractivity 46.66
TPSA ?

Topological Polar Surface Area: Calculated from
Ertl P. et al. 2000 J. Med. Chem.

54.26 Ų

Lipophilicity

Log Po/w (iLOGP)?

iLOGP: in-house physics-based method implemented from
Daina A et al. 2014 J. Chem. Inf. Model.

0.0
Log Po/w (XLOGP3)?

XLOGP3: Atomistic and knowledge-based method calculated by
XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry

2.32
Log Po/w (WLOGP)?

WLOGP: Atomistic method implemented from
Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.

2.62
Log Po/w (MLOGP)?

MLOGP: Topological method implemented from
Moriguchi I. et al. 1992 Chem. Pharm. Bull.
Moriguchi I. et al. 1994 Chem. Pharm. Bull.
Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.

1.63
Log Po/w (SILICOS-IT)?

SILICOS-IT: Hybrid fragmental/topological method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

2.83
Consensus Log Po/w?

Consensus Log Po/w: Average of all five predictions

1.88

Water Solubility

Log S (ESOL):?

ESOL: Topological method implemented from
Delaney JS. 2004 J. Chem. Inf. Model.

-3.06
Solubility 0.197 mg/ml ; 0.000864 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Soluble
Log S (Ali)?

Ali: Topological method implemented from
Ali J. et al. 2012 J. Chem. Inf. Model.

-3.1
Solubility 0.182 mg/ml ; 0.000798 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Soluble
Log S (SILICOS-IT)?

SILICOS-IT: Fragmental method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

-2.57
Solubility 0.619 mg/ml ; 0.00271 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Soluble

Pharmacokinetics

GI absorption?

Gatrointestinal absorption: according to the white of the BOILED-Egg

High
BBB permeant?

BBB permeation: according to the yolk of the BOILED-Egg

Yes
P-gp substrate?

P-glycoprotein substrate: SVM model built on 1033 molecules (training set)
and tested on 415 molecules (test set)
10-fold CV: ACC=0.72 / AUC=0.77
External: ACC=0.88 / AUC=0.94

No
CYP1A2 inhibitor?

Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.83 / AUC=0.90
External: ACC=0.84 / AUC=0.91

No
CYP2C19 inhibitor?

Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.80 / AUC=0.86
External: ACC=0.80 / AUC=0.87

No
CYP2C9 inhibitor?

Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set)
and tested on 2075 molecules (test set)
10-fold CV: ACC=0.78 / AUC=0.85
External: ACC=0.71 / AUC=0.81

No
CYP2D6 inhibitor?

Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set)
and tested on 1068 molecules (test set)
10-fold CV: ACC=0.79 / AUC=0.85
External: ACC=0.81 / AUC=0.87

No
CYP3A4 inhibitor?

Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set)
and tested on 2579 molecules (test set)
10-fold CV: ACC=0.77 / AUC=0.85
External: ACC=0.78 / AUC=0.86

No
Log Kp (skin permeation)?

Skin permeation: QSPR model implemented from
Potts RO and Guy RH. 1992 Pharm. Res.

-6.05 cm/s

Druglikeness

Lipinski?

Lipinski (Pfizer) filter: implemented from
Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev.
MW ≤ 500
MLOGP ≤ 4.15
N or O ≤ 10
NH or OH ≤ 5

0.0
Ghose?

Ghose filter: implemented from
Ghose AK. et al. 1999 J. Comb. Chem.
160 ≤ MW ≤ 480
-0.4 ≤ WLOGP ≤ 5.6
40 ≤ MR ≤ 130
20 ≤ atoms ≤ 70

None
Veber?

Veber (GSK) filter: implemented from
Veber DF. et al. 2002 J. Med. Chem.
Rotatable bonds ≤ 10
TPSA ≤ 140

0.0
Egan?

Egan (Pharmacia) filter: implemented from
Egan WJ. et al. 2000 J. Med. Chem.
WLOGP ≤ 5.88
TPSA ≤ 131.6

0.0
Muegge?

Muegge (Bayer) filter: implemented from
Muegge I. et al. 2001 J. Med. Chem.
200 ≤ MW ≤ 600
-2 ≤ XLOGP ≤ 5
TPSA ≤ 150
Num. rings ≤ 7
Num. carbon > 4
Num. heteroatoms > 1
Num. rotatable bonds ≤ 15
H-bond acc. ≤ 10
H-bond don. ≤ 5

0.0
Bioavailability Score?

Abbott Bioavailability Score: Probability of F > 10% in rat
implemented from
Martin YC. 2005 J. Med. Chem.

0.55

Medicinal Chemistry

PAINS?

Pan Assay Interference Structures: implemented from
Baell JB. & Holloway GA. 2010 J. Med. Chem.

0.0 alert
Brenk?

Structural Alert: implemented from
Brenk R. et al. 2008 ChemMedChem

0.0 alert: heavy_metal
Leadlikeness?

Leadlikeness: implemented from
Teague SJ. 1999 Angew. Chem. Int. Ed.
250 ≤ MW ≤ 350
XLOGP ≤ 3.5
Num. rotatable bonds ≤ 7

No; 1 violation:MW<1.0
Synthetic accessibility?

Synthetic accessibility score: from 1 (very easy) to 10 (very difficult)
based on 1024 fragmental contributions (FP2) modulated by size and complexity penaties,
trained on 12'782'590 molecules and tested on 40 external molecules (r2 = 0.94)

2.24

Application In Synthesis of [ 1001414-56-7 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Downstream synthetic route of [ 1001414-56-7 ]

[ 1001414-56-7 ] Synthesis Path-Downstream   1~7

  • 1
  • [ 215183-27-0 ]
  • [ 1001414-56-7 ]
YieldReaction ConditionsOperation in experiment
95% With hydrogenchloride; In ethyl acetate; for 2.0h; Reactamt (8.322 g, 0.0285 mmol) was dissolved in 150 ml of anhydrous ethyl acetate. The dried HCl was induced continuously for two hours and a large amount of precipitate formed. The solvent was removed and the residue was washed with anhydrous ethyl acetate (3 x 50 ml), ether (3 x 50 ml) in turn to give the product 01-0034-1 (5.862 g), yield: 95%.
  • 2
  • [ 1001414-56-7 ]
  • [ 1035346-03-2 ]
  • [ 1035346-67-8 ]
YieldReaction ConditionsOperation in experiment
With N-ethyl-N,N-diisopropylamine; HATU; In ISOPROPYLAMIDE; at 20.0℃; for 24.0h; 21H. 4-(Aminomethv?-N-((5-bromothiophen-2-v?methv?-l-(7H-pyrrolor2.3- dlpyrimidin-4-yl)piperidine-4-carboxamide; <n="133"/>HATU (419 mg, 1.10 mmol) was added in one portion to 4-((diphenylmethylene- amino)methyl)- 1 -(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxylic acid (440mg, 1.00 mmol), <strong>[1001414-56-7](5-bromothiophen-2-yl)methanamine hydrochloride</strong> (229 mg, 1.00 mmol) and DIPEA (0.699 mL, 4.00 mmol) in DMA (5 ml) at 2O0C under nitrogen. The resulting solution was stirred at 20 0C for 24 hours. The reaction mixture was diluted with EtOAc (100 mL), and washed sequentially with water (2 x 100 mL) and saturated brine (50 mL). The organic layer was dried over MgSO4, filtered and evaporated to afford crude product. The crude product was purified by flash silica chromatography, elution gradient 0 to 10% MeOH in DCM. Pure fractions were evaporated to dryness to afford N-((5-bromothiophen- 2-yl)methyl)-4-((diphenylmethyleneamino)methyl)-l-(7H-pyrrolo[2,3-d]pyrimidin-4- yl)piperidine-4-carboxamide. The product was dissolved in IPA (5.00 ml), water (1 ml) and hydrogen chloride 6N in isopropanol (1.669 ml, 10.01 mmol). The solution was stirred at 20 0C for 24 hours. The crude product was purified by ion exchange chromatography, using an SCX column. The desired product was eluted from the column using 7MNH3/MeOH and pure fractions were evaporated to dryness. The crude gum was triturated with Et20 to give a solid which was collected by filtration and dried under vacuum to give 4-(aminomethyl)-N-((5-bromothiophen-2-yl)methyl)-l-(7H-pyrrolo[2,3-d]pyrimidin-4- yl)piperidine-4-carboxamide (134 mg, 29.8 %) as a white solid. IH NMR (400.13 MHz, DMSO-d6) delta 1.44 - 1.51 (2H, m), 1.79 (2H, s), 2.07 - 2.10 (2H, m), 2.66 (2H, s), 3.40 (2H, d), 4.28 (2H, q), 4.42 (2H, d), 6.56 (IH, d), 6.82 (IH, d), 7.03 (IH, d), 7.15 (IH, d), 8.12 (IH, s), 8.71 (IH, t), 11.62 (IH, s) MS m/e MH+ 451
  • 3
  • [ 1001414-56-7 ]
  • [ 1939-99-7 ]
  • [ 1445720-39-7 ]
YieldReaction ConditionsOperation in experiment
84% With N-ethyl-N,N-diisopropylamine; In dichloromethane; at 20.0℃; for 16.0h; Step 1 : N-((5-Bromothiophen-2-yl)methyl)-l-phenylmethanesulfonamide To a suspension of <strong>[1001414-56-7](5-bromo-2-thienyl)methanamine hydrochloride</strong> (2 g, 8.75 mmol) in dichloromethane (30 mL) was added N,N-diisopropylethylamine (3.2 mL, 18.4 mmol) and the reaction was stirred until complete dissolution. Phenylmethanesulfonyl chloride (1.75 g, 9.18 mmol) was then added and the reaction was stirred at ambient temperature for 16 hours. The reaction was diluted with dichloromethane and washed with water and brine, dried with MgS04, concentrated and purified by silica gel column chromatography (0-100% EtOAc in heptane) to give N-[(5-bromo-2-thienyl)methyl]-l-phenyl-methanesulfonamide (2.55 g, 84% yield). LCMS (m/z) ES+ 364 [M+18]+.
  • 4
  • [ 27757-85-3 ]
  • [ 1001414-56-7 ]
  • 5
  • [ 401485-19-6 ]
  • [ 1001414-56-7 ]
  • 6
  • [ 1001414-56-7 ]
  • [ 1445720-16-0 ]
  • 7
  • [ 1001414-56-7 ]
  • [ 1445720-40-0 ]
 

Historical Records

Technical Information

Categories

Similar Product of
[ 1001414-56-7 ]

Chemical Structure| 612499-04-4

A320639 [612499-04-4]

(5-Bromothiophen-2-yl)methanamine

Reason: Free-salt

Related Functional Groups of
[ 1001414-56-7 ]

Bromides

Chemical Structure| 2160-62-5

A140821 [2160-62-5]

5-Bromothiophene-2-carbonitrile

Similarity: 0.72

Chemical Structure| 4701-17-1

A138385 [4701-17-1]

5-Bromothiophene-2-carbaldehyde

Similarity: 0.69

Chemical Structure| 172319-75-4

A406650 [172319-75-4]

2-Bromo-5-propylthiophene

Similarity: 0.69

Chemical Structure| 25121-87-3

A799759 [25121-87-3]

2,5-Dibromothieno[3,2-b]thiophene

Similarity: 0.69

Chemical Structure| 908494-87-1

A168786 [908494-87-1]

5-Bromo-N-isopropylthiophene-2-carboxamide

Similarity: 0.68

Amines

Chemical Structure| 908494-87-1

A168786 [908494-87-1]

5-Bromo-N-isopropylthiophene-2-carboxamide

Similarity: 0.68

Chemical Structure| 1171697-10-1

A104205 [1171697-10-1]

(4-Bromothiophen-2-yl)methanamine hydrochloride

Similarity: 0.67

Chemical Structure| 58255-18-8

A231996 [58255-18-8]

N-Methyl-1-(thiophen-2-yl)methanamine

Similarity: 0.66

Chemical Structure| 1305712-32-6

A114087 [1305712-32-6]

(S)-1-(Thiophen-2-yl)ethanamine hydrochloride

Similarity: 0.60

Chemical Structure| 548772-41-4

A180707 [548772-41-4]

(5-Chlorothiophen-2-yl)methanamine hydrochloride

Similarity: 0.58